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Background and Aims. Arterial stiffness evaluated as pulse wave velocity, is an early marker of vascular
damage and an independent predictor for cardiovascular events. We investigated if the insulin resis-
tance/hyperinsulinemia chronic hepatitis C virus infection-related could inﬂuence arterial stiffness.
Methods. We enrolled 260 outpatients matched for age, body mass index, gender, ethnicity: 52 with
never-treated uncomplicated chronic hepatitis C virus infection (HCVþ), 104 never-treated hypertensives
(HT) and 104 healthy subjects (NT). Pulse wave velocity was evaluated by a validated system employing
high-ﬁdelity applanation tonometry. We also measured: fasting plasma glucose and insulin, total, LDL-
and HDL-cholesterol, triglyceride, creatinine, e-GFR-EPI, HOMA, quantitative HCV-RNA. Results. HCVþ
patients with respect to NT had an increased pulse wave velocity (7.9 ± 2.1 vs 6.4 ± 2.1 m/s; P < 0.0001),
similar to that observed in HT group (8.8 ± 3.2 m/s). HCVþ patients, in comparison with NT, had higher
triglyceride, creatinine, fasting insulin and HOMA (3.2 ± 1.3 vs 2.5 ± 1.0; P < 0.0001). At linear regression
analysis, the correlation between pulse wave velocity and HOMA was similar in HT (r ¼ 0.380,
P < 0.0001) and HCVþ (r ¼ 0.369, P ¼ 0.004) groups. At multiple regression analysis, HOMA resulted the
major determinant of pulse wave velocity in all groups, explaining respectively 11.8%, 14.4% and 13.6% of
its variation in NT, HT and HCVþ. At correlational analysis hepatitis C virus-RNA and HOMA demonstrated
a strong and linear relationship between them, explaining the 72.4% of their variation (P ¼ 0.022).
Conclusions. We demonstrated a signiﬁcant and direct correlation between HOMA and pulse wave
velocity in HCVþ patients, similar to that observed in hypertensives.
© 2014 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Abnormal arterial stiffness is associated with an increased risk
for various adverse outcomes, including cardiovascular disease
[1,2], stroke [2,3], and renal disease [4]. Interestingly, arterial stiff-
ness is associated with traditional cardiovascular risk factors and
metabolic alterations including obesity, impaired glucose tolerancental and Clinical Medicine,
00 Catanzaro, Italy.
Perticone).
rved.(IGT), and dyslipidemia [5]. In addition, it reﬂects the structural
arterial wall modiﬁcations, characterizing the vascular aging [6].
There are several evidences demonstrating that patients with
chronic hepatitis C virus (HCV) infection (HCVþ) have an increased
cardiovascular morbidity and mortality. In keeping with this, we
recently demonstrated that HCVþ patients have an increased left
ventricular mass, similar to that of hypertensive subjects [7],
mediated by hyperinsulinemia/insulin-resistance (IR) status and
independently of other confounding factors [8]. These evidences
have a biological plausibility because HCVþ patients are insulin
resistant as consequence of direct and indirect mechanisms, lead-
ing to both hepatic and extra-hepatic IR. In addition, the abnormal
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tion with the renineangiotensinealdosterone system [9e11].
However, all these mechanisms do not fully justify the higher
cardiovascular risk of these patients. Taken together, the aim of this
study was to evaluate the possible association between HCVþ
infection and abnormal arterial stiffness in comparison with a
group of hypertensive patients and a group of normotensive health
subjects.
2. Methods
2.1. Study population
To test our hypothesis we designed a caseecontrol study
involving patients evaluated at the University Hospital of Cata-
nzaro. We recruited 52 HCVþ normotensive Caucasian outpatients
(40 males and 12 females, mean age 48.73 þ 10.4 years). They were
matched for age, body mass index and gender in a 1:2:2 ratio with
208 subjects participating to the CAtanzaro MEtabolic RIsk factors
Study (CATAMERIS), 104 never treated hypertensives (HT) (77
males and 27 females, mean age 48.5 þ 9.7 years) and 104 nor-
motensives (NT) (79 males and 25 females, mean age 48.8 þ 11.2
years). At the time of the ﬁrst evaluation, both HCVþ and HT pa-
tients were untreated with antiviral therapy or antihypertensive
drugs. Secondary forms of hypertension were excluded by sys-
tematic testing by a standard clinical protocol including renal ul-
trasound studies, computed tomography, renal scan,
catecholamine, plasma renin activity and aldosterone measure-
ments. Other exclusion criteria were type-2 diabetes mellitus
(T2DM) detected by an oral glucose tolerance test, according to ADA
guidelines; history or clinical evidence of angina, myocardial
infarction, valvular heart disease, cardiomyopathy, heart failure or
peripheral vascular disease; administration of any drugs interfering
with glucose metabolism; kidney, thyroid, endocrine and advanced
liver diseases, transplanted patients, history of malignant disease.
We collected measurements of height and weight according to a
standardized protocol, and body mass index was calculated as ki-
lograms per square meter. The Ethical Committee approved the
protocol and informed written consent was obtained from all par-
ticipants. All the investigations were performed in accordance with
the principles of the Declaration of Helsinki.
2.2. Blood pressure measurements
Readings of clinic blood pressure (BP) were obtained in the left
arm of the supine patients, after 5 min of quiet rest, with a mercury
sphygmomanometer. Minimum three BP readings were taken on
three separate occasions at least 2 weeks apart. Systolic and dia-
stolic BP was recorded at the ﬁrst appearance (phase I) and the
disappearance (phase V) of Korotkoff sounds. Baseline BP values
were the average of the last two of the three consecutive mea-
surements obtained at intervals of 5 min. Patients with a clinic
systolic BP (SBP)> 140mmHg and/or diastolic BP (DBP)> 90mmHg
were deﬁned as hypertensive.
2.3. Laboratory determinations
All laboratory measurements were performed after 12 h of
fasting. Plasma glucose was determined immediately by the
glucose oxidation method [Glucose analyzer, Beckman Coulter,
Milan; intra-assay coefﬁcient of variation (CV) 2.2%, inter-assay CV
3.8%]. Serum insulin was determined in duplicate by a highly spe-
ciﬁc radioimmunoassay using two monoclonal antibodies; intra-
assay CV 2.1%, inter-assay CV 2.9%. IR was estimated by homeo-
stasis model assessment (HOMAIR) according to the followingequation: HOMA ¼ [insulin (mU/ml) * glucose (mmol/l)]/22.5 [12].
Total, low-density lipoproteine (LDL), and high-density lipoprotein
e (HDL) cholesterol and triglyceride concentrations weremeasured
by enzymatic methods (Roche Diagnostics GmbH, Mannheim,
Germany). Creatinine was measured by using Jaffe methodology.
Values of estimated glomerular ﬁltration rate (mL/min/1.73 m2)
were calculated by using the equation proposed by investigators in
the chronic kidney disease epidemiology (CKD-EPI) collaboration
[13]. Quantitative HCV-RNAwas assayed by a real-time polymerase
chain reaction (PCR) assay.
2.4. Arterial wave reﬂection and central BP measurements
These measurements were obtained by a validated system
(Sphygmocor™; AtCor Medical, Sydney, Australia) that employs
high-ﬁdelity applanation tonometry (Millar) and appropriate
computer software for the analysis of pressure wave (Sphygmo-
cor™). Pressure calibration was obtained through automatically,
non-invasively recorded supine brachial artery BP of the dominant
arm after a 30-min rest (Dinamap Compact T; Johnson & Johnson
Medical Ltd, Newport, UK). BP was measured ﬁve times over 10min
and the mean of the last three measurements were taken for cali-
bration. Pressurewave recording was performed at the radial artery
of the dominant arm with the wrist softly hyperextended, and it is
the average of single pressure waves recorded consecutively for
eight seconds. Pressure wave recordings were accepted only if
variation of peak and bottom pressures of single pressure waves
was <5%. The central pressure wave was automatically derived
from the radial pressures by a built-in generalized transfer function.
In addition, was also obtained pressure wave measurement at the
right carotid artery, as it is well known that central AI may be more
accurately derived from this vascular site [14]. Central waveforms
were further analyzed to identify the time to peak/shoulder of the
ﬁrst (T1) and second (T2) pressure wave components during sys-
tole. The pressure at the peak/shoulder of T1 was identiﬁed as
outgoing pressure wave height (P1), the pressure at the peak/
shoulder of T2 was identiﬁed as the reﬂected pressure wave height
(P2), either absolutely or as percent of ejection duration.
Augmentation pressure (AP) was deﬁned as difference between
P2eP1, and augmentation index (AI) as [AP/pulse pressure (PP)]
*100. Aortic pulse wave velocity (PWV) was determined from ca-
rotid and femoral pressure waveforms. Carotid to femoral transit
time (DT) was computed from the foot-to-foot time difference be-
tween carotid and femoral waveforms. The distance between the
surface markings of the sternal notch and femoral artery was used
to estimate the path length between the carotid and femoral ar-
teries (L), and PWV computed as L/DT.
2.5. Statistical analysis
ANOVA for continuous clinical and biological data was per-
formed to test the differences among groups, and the Bonferroni
post-hoc test for multiple comparisons was further performed; for
dichotomic variables we used the c2 test. Data are expressed as
mean ± SD, and binary data as percent frequency. Correlation co-
efﬁcients were calculated according to Pearson's method. The in-
dependent relationship between PWV and HOMAwas investigated
by univariate and multiple linear regression analysis, in the whole
study population and in the three groups separately. In the multi-
variate model we inserted only HOMA to avoid a possible colin-
earity with fasting glucose and insulin. To infer the involvement of
insulin sensitivity (assessed by HOMA) in the pathophysiological
pathway by which hypertension and HCV lead to increased PWV in
our study population we applied the analytical approach proposed
by Kraemer et al. [15]. We ﬁrst estimated the crude (model 1) and
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PWV (by unadjusted and adjusted multiple linear regression
analysis). In model 2 we included a series of potential confounders
(BP, LDL and HDL cholesterol) but HOMA (i.e. the potential mediator
of the effect of hypertension/HCV on PWV). To unravel the potential
role of insulin sensitivity in the pathway linking hypertension/HCV
and arterial rigidity, we introduced HOMA index in model 3 and we
calculated the percent change in the beta value for the links be-
tween hypertension/HCV and PWV. The percentage reduction in
the beta values is an index of the total amount of covariance be-
tween hypertension/HCV and PWV that is explained by insulin
resistance. Data are expressed in terms of standardized regression
coefﬁcients (b) and P values. Differences were assumed to be sig-
niﬁcant at P < 0.05. All calculations were done with a standard
statistical package (SPSS for Windows version 16.0, Chicago, IL,
USA).3. Results
3.1. Study population
Study population characteristics are reported in Table 1. Among
three groups there were signiﬁcant differences for central SBP (c-
SBP), central DBP (c-DBP) and central pulse pressure (c-PP). InTable 1
Demographic, clinical, humoral and echocardiographic data of the study population
and of the three groups separately.
All
(n ¼ 260)
NT
(n ¼ 104)
HCVþ
(n ¼ 52)
HT
(n ¼ 104)
P value
Age, years 48.6 ± 10.4 48.8 ± 11.1 48.7 ± 10.4 48.5 ± 9.7 0.972
Sex, M/F 196/64 79/25 40/12 77/27 0.883**
BMI, Kg/m2 27.8 ± 4.5 28.0 ± 5.5 27.4 ± 2.6 27.8 ± 4.3 0.742
WC, cm 95.8 ± 8.3 95.0 ± 9.4 96.0 ± 5.3 95.34 ± 8.4 0.347
Current
smokers, n
(%)
73 (28) 15 (14) 29 (56) 29 (28) <0.0001**
Systolic BP,
mmHg
134 ± 15 126 ± 12 124 ± 8x 147 ± 9* <0.0001
Diastolic BP,
mmHg
81 ± 10 77 ± 8 74 ± 7#x 90 ± 6* <0.0001
PP, mmHg 52 ± 11 49 ± 10 50 ± 8x 57 ± 11* <0.0001
Heart rate, bpm 68 ± 9 69 ± 10 66 ± 7 69 ± 8 0.086
c-SBP, mmHg 116 ± 17 108 ± 14 109 ± 13 128 ± 14 <0.0001
c-DBP, mmHg 68 ± 13 64 ± 11 66 ± 8 73 ± 15 <0.0001
c-PP, mmHg 48 ± 18 44 ± 17 43 ± 13 55 ± 19 <0.0001
PWV, m/s 7.7 ± 2.8 6.4 ± 2.1 7.9 ± 2.1 8.8 ± 3.2 <0.0001
AI, % 18.9 ± 11.1 16.1 ± 12.0 20.2 ± 7.9 21.2 ± 10.9 0.002
AP, mmHg 10 ± 7 8 ± 7 9 ± 5 13 ± 8 <0.0001
Total
cholesterol,
mmol/l
4.91 ± 0.83 4.83 ± 0.78 187 ± 33 195 ± 31 0.206
LDL-cholesterol,
mmol/l
3.15 ± 0.83 2.97 ± 0.75 3.05 ± 0.90x 3.39 ± 0.80* <0.0001
HDL-
cholesterol,
mmol/l
1.14 ± 0.26 1.27 ± 0.26 1.03 ± 0.21# 1.03 ± 0.23* 0.466
Triglyceride,
mmol/l
1.37 ± 0.41 1.30 ± 0.43 1.61 ± 0.34#x 1.30 ± 0.37 <0.0001
Creatinine,
mmol/l
63.4 ± 8.8 63.4 ± 8.8 71.3 ± 8.8#x 66.9 ± 8.8 <0.0001
e-GFR, ml/min/
1.73 m2
106 ± 11 107 ± 11 103 ± 10 105 ± 12 0.101
Fasting glucose,
mmol/l
5.17 ± 0.56 5.11 ± 0.56 5.22 ± 0.61 5.11 ± 0.61 0.479
Fasting insulin,
U/ml
13.1 ± 5.4 11.2 ± 4.5 14.1 ± 5.5# 14.5 ± 5.6* <0.0001
HOMA 3.0 ± 1.3 2.5 ± 1.0 3.2 ± 1.3# 3.3 ± 1.3* <0.0001
* ¼ P < 0.05 by Bonferroni HT vs NT; # ¼ P < 0.05 by Bonferroni HCVþ vs NT;
x ¼ P < 0.05 by Bonferroni HCVþ vs HT; ** tested by chi-square test.particular, as expected, these parameters were signiﬁcantly higher
in HT group in comparison with both NT and HCVþ subjects,
without any signiﬁcant difference between these two groups.
Clinically relevant, PWV, AP and AI. In particular, all these central
hemodynamic parameters progressively increase from NT, to HCVþ
and HT patients. Interestingly, HCVþ patients, respect to healthy
normotensive subjects, had an increased PWV (7.9 ± 2.1 vs
6.4 ± 2.1 m/s; P < 0.0001), similar to that observed in HT group
(8.8 ± 3.2 m/s). In addition, regarding biochemical variables, HCVþ
patients, in comparison with NT healthy subjects, had higher tri-
glyceride, creatinine, fasting insulin and HOMA. Of interest, no
differences were found in HOMA values between HT and HCVþ
(3.2 ± 1.3 vs 3.3 ± 1.3; P ¼ 0.651) patients. Similarly, in HCVþ group
there was a signiﬁcant higher prevalence of smokers. The mean
value of HCV-RNA was 3868 ± 2963  103 (UI/ml) in HCVþ.3.2. Correlational analysis
A linear regression analysis was performed to test the rela-
tionship between PWV and different covariates in the whole study
population and in the three groups separately (Table 2).
In thewhole study population, PWVwas signiﬁcantly correlated
with SBP (r ¼ 0.331; P ¼ 0.0001), DBP (r ¼ 0.146; P ¼ 0.009), PP
(r ¼ 0.306; P ¼ 0.0001), c-SBP (r ¼ 0.222; P ¼ 0.0001), c-PP
(r ¼ 0.222; P ¼ 0.0001), glycemia (r ¼ 0.171; P ¼ 0.003), fasting
insulin (r ¼ 0.425; P ¼ 0.003), HOMA (r ¼ 0.425; P ¼ 0.001), and
inversely correlated with HDL-cholesterol (r ¼ 0.175; P ¼ 0.002).
In HT group, a linear relationship was observed between PWV
and fasting insulin (r ¼ 0.316; P ¼ 0.001) and HOMA (r ¼ 0.380;
P ¼ 0.0001). In addition, in this group, the other covariates signif-
icantly correlated with PWV were SBP (r ¼ 0.299; P ¼ 0.001), PP
(r ¼ 0.321; P ¼ 0.0001), c-PP (r ¼ 0.259; P ¼ 0.004), and glycemia
(r ¼ 0.285; P ¼ 0.002).
In HCVþ group, PWV resulted statistically correlated with fast-
ing insulin (r ¼ 0.402; P ¼ 0.002) and HOMA (r ¼ 0.369; P ¼ 0.004).Table 2
Linear regression analysis between PWV and different covariates in the whole
population and in the three groups.
All (n. 260) NT (n. 104) HT (n. 104) HCVþ (n. 52)
r/P r/P r/P r/P
Age, yrs 0.25/0.345 0.172/0.041 0.088/0.187 0.305/0.014
Gender, M/F 0.017/0.391 0.76/0.221 0.036/0.359 0.135/0.170
BMI, kg/m2 0.001/0.497 0.073/0.231 0.048/0.315 0.037/0.396
SBP, mmHg 0.331/0.0001 0.023/0.408 0.299/0.001 0.220/0.059
DBP, mmHg 0.146/0.009 0.093/0.174 0.174/0.039 0.154/0.138
PP, mmHg 0.306/0.0001 0.095/0.168 0.321/0.0001 0.088/0.267
c-SBP, mmHg 0.222/0.0001 0.014/0.444 0.095/0.169 0.073/0.303
c-DBP, mmHg 0.028/0.328 0.033/0.371 0.253/0.005 0.049/0.365
c-PP, mmHg 0.222/0.0001 0.033/0.371 0.259/0.004 0.107/0.224
Cholesterol,
mmol/l
0.065/0.148 0.097/0.162 0.076/0.223 0.135/0.170
LDL-cholesterol,
mmol/l
0.104/0.047 0.064/0.261 0.039/0.345 0.153/0.139
HDL-cholesterol,
mmol/l
0.175/0.002 0.107/0.139 0.032/0.372 0.101/0.237
Triglyceride,
mmol/l
0.066/0.144 0.009/0.463 0.128/0.098 0.006/0.482
Creatinine, mmol/l 0.053/0.199 0.013/0.446 0.017/0.430 0.096/0.250
CKD-Epi, ml/min/
1.73 m2
0.039/0.267 0.173/0.039 0.116/0.121 0.304/0.434
Glycemia, mmol/l 0.171/0.003 0.110/0.132 0.285/0.002 0.024/0.434
Fasting insulin,
mU/l
0.425/0.003 0.314/0.001 0.316/0.001 0.402/0.002
HOMA 0.425/0.001 0.344/0.0001 0.380/0.0001 0.369/0.004
Table 4
Multivariate analysis of PWV at increasing complexity of data adjustment.
Beta aReduction in beta value (%) P
Model 1
Hypertensive status (versus NT) 0.396 … <0.0001
HCV status (versus NT) 0.218 … 0.001
Model 2
Hypertensive status (versus NT) 0.309 22% 0.001
HCV status (versus NT) 0.202 7.3% 0.00
Model 3
Hypertensive status (versus NT) 0.229 26% 0.01
HCV status (versus NT) 0.143 29% 0.02
Model 1 ¼ Hypertensive status þ HCV status.
Model 2 ¼ Model 1 þ systolic and diastolic BP, LDL- and HDL-cholesterol.
Model 3 ¼ Model 2 þ HOMA.
HOMA ¼ homeostasis model assessment.
NT ¼ normotensive healthy subjects.
a The reductions in beta values between the two key exposures (hypertensive and
HCV status) and the dependent variable (PWV) in models of increasing complexity
of data adjustment were calculated as percentage reductions in this parameter
between each multivariate model from the previous one.
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A stepwise multivariate linear regression model was performed
to evaluate the independent predictors of PWV in all population
and in the three groups separately (Table 3). In this analysis we
included as independent covariates also the gender and the
smoking in addition to those resulted signiﬁcant in the linear
regression. In the whole population, as well as in HT and HCVþ
groups, HOMA was the major predictor of PWV, explaining 18.0%,
14.4% and 13.6% of its variation, respectively. In the whole popu-
lation, other independent predictors were SBP and DBP, explaining
respectively another 7.3% and 1.3% of PWV variation; in HT group,
SBP adds another 6.5% in the PWV variation, while in HCVþ group
e-GFR resulted another independent predictor, explaining an
additional 8.2% of its variation.
To test the hypothesis that HOMA is a mediator of the link be-
tween hypertensive/HCV status and PWV we constructed multi-
variate linear regression models of increasing complexity of data
adjustment (Table 4). In model 1, both hypertensive (beta ¼ 0.396,
P < 0.001) and HCV status (beta ¼ 0.218, P ¼ 0.001) were strongly
and signiﬁcantly related to PWV. The strength of the hypertensive
status-PWV link was critically dependent on potential confounders
(namely: systolic and diastolic BPs, LDL and HDL cholesterol)
because data adjustment for these covariates (model 2) reduces by
22% the strength of this association. Of note, the HCV status-PWV
link was only slightly affected by data adjustment for the same
set of confounders (model 2, 7.3%) suggesting that such a link is
largely unexplained by these risk factors. Notably, data adjustment
for HOMA (model 3) further reduces the strength of the associa-
tions between hypertensive status and PWV (26%) and evenmore
the relationship between HCV status and the same outcome vari-
able (29%) indicating that about 1/3 of the relationship between
hypertension and HCV status with PWV is mediated by insulin
resistance. Of interest, in none of the models, smoking was retained
as independent predictor of vascular damage.4. Discussion
The results of this study demonstrate, for the ﬁrst time, that
HCVþ normotensive patients, in comparison with healthy normo-
tensive subjects, have a signiﬁcant increase of arterial stiffness
assessed by PWV, an important surrogate end-point for cardio-
vascular morbidity and mortality [1e5]. In fact, HCVþ group pre-
sents higher values of PWV than that found in NTgroup, similarly to
that observed in hypertensive patients. These ﬁndings have clinical
relevance because contribute to expand previous knowledge about
the pathogenetic mechanisms underlying the high prevalence ofTable 3
Multivariate analysis of PWV in whole population and in the three groups.
r2 partial r2 total P
All
HOMA 18.0 18.0 <0.0001
SBP, mmHg 7.3 25.3 <0.0001
DBP, mmHg 1.3 26.6 0.036
NT
HOMA 11.8 11.8 0.001
HT
HOMA 14.4 14.4 <0.0001
SBP, mmHg 6.5 20.9 0.005
HCVþ
HOMA 13.6 13.6 0.007
e-GFR, ml/min/1.73 m2 8.2 21.8 0.028
HOMA ¼ homeostasis model assessment; SBP ¼ systolic blood pressure;
DBP ¼ diastolic blood pressure.cardiovascular morbidity andmortality in this setting of patients. In
fact, there are consolidated evidences demonstrating that
abnormal arterial stiffness, reﬂecting the arterial wall modiﬁca-
tions, is a powerful and independent predictor for various adverse
cardiovascular outcomes [1e5].
Vascular stiffness, that represents an intermediate step of
vascular aging, is due to the prolonged exposure to traditional and
non-traditional cardiovascular risk factors, such as IR/hyper-
insulinemia [6]. The biological plausibility of this ﬁnding is also
supported by present results demonstrating that, in the multiple
regression analysis HOMA was retained as the ﬁrst and indepen-
dent predictor of PWV in the whole population, as well as in HT and
HCVþ groups, explaining 18.0%, 14.4% and 13.6% of its variation,
respectively. Of clinical relevance, the signiﬁcant association
documented in HCVþ patients between HOMA/hyperinsulinemia
and PWV conﬁrms previously published data demonstrating a
strict relationship between HCVþ infection and the development of
IR, through a direct interaction between viral products and insulin
signaling pathway via IRS-1-PI3-kinase-Akt [16e18]. Clinically
relevant, these data are not inﬂuenced by the smoking because it
was not retained as independent predictor of vascular damage
neither in the whole population nor in the HCVþ group.
An additional ﬁnding of this study is that in HCVþ patients an
additional independent predictor of PWV is the estimated
glomerular ﬁltration rate, another independent predictor of
vascular damage [19,20] and cardiovascular events [21,22]. This is
not surprising because we have previously demonstrated that IR/
hyperinsulinemia, associated with a reduction in circulating levels
of insulin growth factor-1, impairs the renal function through
changes in renal blood ﬂow and renal vascular resistance [23]. All
these conditions interact between them in a multiplicative manner
amplifying the progression of vascular damage that represents an
early step in the pathophysiology of atherosclerotic disease. In
keeping with this, our data contribute to explain one of the possible
pathogenetic mechanism linking the HCV infection to atheroscle-
rosis [24,25].
Of clinical relevance, at this mechanism also participate the in-
crease of the aortic hemodynamic parameters, such as AI that re-
ﬂects the degree of aortic compliance. In fact, the aorta buffering
the pulsatile energy generated by the heart at each cardiac cycles,
decreases both the afterload and stroke work [1,5]. In this way, it
operates in reducing cardiac work and preventing the cardiac hy-
pertrophy and modulating nitric oxide bioavailability that exerts
several protective effects on vascular wall. In keeping with this, we
M. Perticone et al. / Atherosclerosis 238 (2015) 108e112112recently demonstrated that AI heart rate-related is signiﬁcantly
correlatedwith endothelium-dependent vasodilation; in particular,
the reduction of AI is associated with an increase on nitric oxide
bioavailability [26].
5. Conclusions
Chronic HCVþ inﬂammation, through its metabolic and proin-
ﬂammatory effects, interferes with the structure of arterial wall
promoting atherogenesis through direct and indirect mechanisms;
so, it could be regarded as a new factor for cardiovascular risk.
Based on these evidences, it is desirable to better deﬁne the risk
proﬁle in HCVþ subjects and therefore it is reasonable to recom-
mend the detection of subclinical organ damage, such as vascular
stiffness.
6. Study limitations
In this study we did not perform liver biopsy because the
diagnosis of HCV infection has been made on the basis of clinical
and laboratory data, as recommended by the Guidelines.
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